Tiotropium Efficacy Against Allergen Induced Early Asthmatic Responses

NCT ID: NCT04648813

Last Updated: 2021-09-30

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-11-13
• Study Completion Date: 2021-04-20

Brief Summary

The study will compare the effect of inhaled tiotropium versus placebo on allergen induced early asthmatic responses in individuals with atopic asthma.

Detailed Description

This is a single center, double-blind, randomized, placebo-controlled, crossover study. The study will consist of two one week treatment periods, one with tiotropium (two inhalations/5mcg/day) and one with placebo (2inhalations/day). A minimum two week washout period between treatments is required. Four visits over the course of approximately 4 weeks will be required to complete the study. Procedures at each visit are as follows:

Visit 1:

Participants will undergo consent procedures and if consent is provided measurements of FeNO, spirometry, airway responsiveness to methacholine, skin prick testing, skin titration endpoint testing and sputum induction will be performed. If participants meet eligibility criteria following these assessments, treatment 1 will be dispensed and the first dose administered. The participant will then self administer the treatment for the next six days (i.e. a total of 7 days of treatment) before returning for Visit 2.

Visit 2:

A final dose of treatment 1 will be administered. At 30 minutes post dose, FeNO testing, spirometry measurements and allergen inhalation challenge will be performed. Five hours after the allergen challenge, FeNO will again be measured and sputum induction will be performed.

Visits 3 and 4:

Visits 3 and 4 will be identical to Visit 1 and 2 except that no skin prick testing or skin titration endpoint testing will be required. At Visit 3 participants will be crossed over to treatment 2 and the first dose will be administered. Participants will self administer treatment 2 for the next six days before returning for Visit 4.

The primary endpoint will be the EAR PD20, the amount of allergen required to induce an early asthmatic response (i.e. a fall in FEV1 post allergen inhalation of 20% or more) tiotropium versus placebo.

Conditions

Allergic Asthma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

tiotropium bromide monohydrate (Spiriva Respimat)

Group Type: EXPERIMENTAL

tiotropium bromide monohydrate (Spiriva Respimat)

Intervention Type: DRUG

administered daily, 2 inhalations/5mcg per dose for a total of 8 doses

matching placebo

Group Type: PLACEBO_COMPARATOR

matching placebo

Intervention Type: DRUG

administered daily, 2 inhalations per dose for a total of 8 doses

Interventions

tiotropium bromide monohydrate (Spiriva Respimat)

administered daily, 2 inhalations/5mcg per dose for a total of 8 doses

Intervention Type: DRUG

matching placebo

administered daily, 2 inhalations per dose for a total of 8 doses

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• signed informed consent
• diagnosis of mild asthma with a minimum 3 months history at the time of enrolment into the trial
• pre-bronchodilator FEV1 80% or greater than the predicted value
• positive response to inhaled methacholine (i.e. MCh PD20 ≤ 400mcg)
• evidence of atopy (i.e. positive skin prick test to an allergen that is appropriate for use in allergen inhalation challenge)
• no respiratory infection within 4 weeks of Visit 1
• no allergen exposure within 4 weeks of Visit 1
• current non-smoker (ex-nicotine smoker with < 10 pack years evaluated case by case)
• use of β2 agonist rescue medications less than daily and no more than 4 times per week
• general good health with no other medical condition, medication use or lifestyle activities that would potentially alter the outcome of the allergen challenge

Exclusion Criteria

• currently pregnant or breast-feeding
• current daily use of other inhaled recreational products (e.g. cannabis, e-cigarettes or other vaping products; occasional use requires 24 hour withhold)
• diagnosis or evidence of narrow angle glaucoma
• diagnosis or evidence of urinary retention
• known hypersensitivity to tiotropium, atropine or its derivatives (e.g. ipratropium) or components of tiotropium formulation (e.g. benzalkonium chloride)
• history of anaphylaxis or angioedema
• current use of :
• inhaled corticosteroid including combination therapies
• inhaled muscarinic antagonists - except study treatment (e.g. ipratropium bromide)
• long-acting beta2-agonists (LABA; e.g. formoterol)
• leukotriene receptor antagonists (e.g. montelukast)
• biologics (e.g. benralizumab)
• allergen immunotherapy
• mast cell stabilizers (e.g. nedocromil sodium)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Saskatchewan

OTHER

Sponsor Role: lead

Responsible Party

Beth Davis

Research Scientist

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Asthma Research Lab University of Saskatchewan Room 346 Ellis Hall

Saskatoon, Saskatchewan, Canada

Countries

Canada

Other Identifiers

BIO REB 1959

Identifier Type: -

Identifier Source: org_study_id